Drug Information

Drug (ID: DG01823) and It's Reported Resistant Information

• Name: Formononetin
• Synonyms: Formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; Neochanin; 4'-O-methyldaidzein; Flavosil; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; UNII-295DQC67BJ; MFCD00016948; NSC 93360; 7-Hydroxy-3-(4-methoxyphenyl)chromone; CHEBI:18088; Isoflavone, 7-hydroxy-4'-methoxy-; NSC-93360; 295DQC67BJ; NSC93360; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; SMR000470932; SR-01000765510; EINECS 207-623-9; formononetine; Formonentin; Formoononetin; Myconate; Mycotech; 7-hydroxy-4'-methoxy-isoflavone; Formononetin,(S); Spectrum_000373; SpecPlus_000223; Daidzein 4-methyl ether; Spectrum2_000560; Spectrum3_000660; Spectrum4_001429; Spectrum5_000258; DSSTox_CID_2311; Formononetin (Formononetol); DSSTox_RID_76544; NCIOpen2_005983; DSSTox_GSID_22311; Oprea1_139748; Oprea1_815287; SCHEMBL62915; BSPBio_002299; KBioGR_001878; KBioSS_000853; SPECTRUM102007; MLS000697593; MLS006011897; BIDD:ER0119; DivK1c_006319; SPBio_000639; CHEMBL242341; 7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; DTXSID4022311; Formononetin, analytical standard; KBio1_001263; KBio2_000853; KBio2_003421; KBio2_005989; KBio3_001519; HMS1922N18; HMS2231I04; HMS3369C07; HMS3655N22; ALBB-030789; BCP29929; Formononetin, >=99.0% (TLC); HY-N0183; TNP00176; Tox21_301848; BBL010458; BDBM50021398; CCG-38727; LMPK12050037; s2299; STK801612; ZINC18847036; AKOS000270811; AC-8001; DB15335; MCULE-4171151967; SDCCGMLS-0066428.P001; 7-hydroxy-4'-methoxy-Isoflavone (8CI); NCGC00017269-01; NCGC00017269-02; NCGC00017269-03; NCGC00017269-04; NCGC00017269-05; NCGC00017269-06; NCGC00017269-07; NCGC00095207-01; NCGC00095207-02; NCGC00095207-03; NCGC00178715-01; NCGC00255167-01; AS-11642; CAS-485-72-3; NCI60_042081; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); Neochanin; Flavosil;NEOCHANIN;Formononetol; F0868; FT-0626540; FT-0632204; K-080; N1625; SW219915-1; C00858; AB00052676-07; 485F723; A827555; AE-641/01968055; Q408859; 7-hydroxy-3-(4-methoxyphenyl)-1-benzopyran-4-one; Q-100540; SR-01000765510-3; SR-01000765510-4; BRD-K55567017-001-02-4; BRD-K55567017-001-06-5; F3139-1207; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one(9CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); Formononetin, United States Pharmacopeia (USP) Reference Standard; 7-Hydroxy-3-(4-methoxyphenyl)chromone, 7-Hydroxy-4'-methoxyisoflavone; Biochanin B; Flavosil; Formononetol; NSC 93360; NSC93360; NSC-93360
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; [1]
• Target: SLC5A2 messenger RNA (SLC5A2 mRNA); SC5A2_HUMAN; [1]
• Formula: 2
• IsoSMILES: COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O
• InChI: InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3
• InChIKey: HKQYGTCOTHHOMP-UHFFFAOYSA-N
• PubChem CID: 5280378
• ChEBI ID: CHEBI:18088
• TTD Drug ID: D0M7BR
• INTEDE ID: DR00955
• DrugBank ID: DB15335

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Ewing sarcoma associated transcript 1 (EWSAT1) [1]

• Resistant Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Molecule Alteration: Up-regulation; Expression
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: human umbilical vein endothelial cells; N.A.; Homo sapiens (Human); N.A.
• In Vivo Model: Female SD rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Microarray assay; qRT-PCR; Western bloting analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Formononetin, J1 and J2 have different effects on endothelial cells via EWSAT1-TRAF6 and its downstream pathway.

Unspecified malignant neoplasms of unspecified sites [ICD-11: 2D4Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ATPase [2]

• Sensitive Disease: multidrug resistance cancer [ICD-11: 2D4Z]
• Molecule Alteration: .; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: ABCB1/Flp-InTM-293 cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: P-gp ATPase assay
• Experiment for Drug Resistance: SRB assay
• Mechanism Description: This study demonstrated the finding of a natural product, formononetin, which is a potent inhibitor of human P-gp via uncompetitive inhibition and ATPase stimulation. Formononetin resensitized MDR cancer cells to chemotherapeutic drugs.

Key Molecule: ATPase [2]

• Sensitive Disease: multidrug resistance cancer [ICD-11: 2D4Z]
• Molecule Alteration: .; .
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Zebrafish xenograft model; Zebrafish
• Experiment for Molecule Alteration: P-gp ATPase assay
• Experiment for Drug Resistance: Zebrafish xenograft assay
• Mechanism Description: This study demonstrated the finding of a natural product, formononetin, which is a potent inhibitor of human P-gp via uncompetitive inhibition and ATPase stimulation. Formononetin resensitized MDR cancer cells to chemotherapeutic drugs.

References

• Ref 1: Formononetin, J1 and J2 have different effects on endothelial cells via EWSAT1-TRAF6 and its downstream pathwayJ Cell Mol Med. 2020 Jan;24(1):875-885. doi: 10.1111/jcmm.14797. Epub 2019 Nov 19.
• Ref 2: Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. Int J Mol Sci. 2024 Aug 2;25(15):8471.